Business
ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation
CULVER CITY, Calif., May 22, 2026--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced new survey data highlighting the diverse treatment preferences and decision-making priorities of patients with Bacillus Calmette–Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC). The findings were presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2026, May 17–20, 2026, at the Pennsylvania Convention C
About this update from Immunitybio, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":270,"url":"https://media.zenfs.com/en/business-wire.com/e16a0fda524122a87fbcce3d378f1d64"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OizUgY.6lHMBz0vc1qzZkA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MA--/https://media.zenfs.com/en/business-wire.com/e16a0fda524122a87fbcce3d378f1d64","width":480,"height":270},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/JojWpwWQA804nCyB_Q_I_w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTM2MA--/https://media.zenfs.com/en/business-wire.com/e16a0fda524122a87fbcce3d378f1d64","width":480,"height":270}},"lazy":false},{"type":"text","content":"UK-based study identifies key patient-centered factors influencing treatment preferences in high-risk NMIBC","length":107,"tagName":"p","attribs":{}},{"type":"text","content":"CULVER CITY, Calif., May 22, 2026--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced new survey data highlighting the diverse treatment preferences and decision-making priorities of patients with Bacillus Calmette–Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC). The findings were presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2026, May 17–20, 2026, at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.","length":553,"tagName":"p"},{"type":"text","content":"The mixed-methods study, conducted in partnership with Fight Bladder Cancer, a UK-based patient advocacy organization, explored how patients with NMIBC who were currently receiving or had previously received BCG weigh radical cystectomy against bladder-sparing therapies following BCG treatment failure. The study provides a contemporary, patient-centered perspective on the factors influencing treatment decision-making in this setting.","length":437,"tagName":"p"},{"type":"text","content":""Treatment decisions for patients with BCG-unresponsive NMIBC are deeply personal and often complex," said Patrick Soon-Shiong, M.D., Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. "These findings reinforce the importance of incorporating patient perspectives, quality-of-life considerations, and individual t...